Last reviewed · How we verify
NCT06786936: ELATE
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
trial testing Secukinumab in Psoriatic Arthritis in 50 participants. Currently enrolling.
28 February 2027
Quick facts
| Lead sponsor | NHS Greater Glasgow and Clyde |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 2 June 2025 |
| Primary completion | 28 February 2027 |
| Estimated completion | 30 April 2027 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Secukinumab (secukinumab) — full drug profile →
- Bimekizumab (BIMEKIZUMAB) — full drug profile →
- Ixekizumab (ixekizumab) — full drug profile →
- Placebo
Conditions studied
- Psoriatic Arthritis — all drugs for Psoriatic Arthritis →
- Depression — all drugs for Depression →
- Psoriatic Plaque — all drugs for Psoriatic Plaque →
Sponsor
NHS Greater Glasgow and Clyde — full company profile →
Who can join
Adults 18 to 74, any sex, with Psoriatic Arthritis or Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators seek clinically actionable understanding of the mechanisms that underlie depression in the context of immune mediated inflammatory diseases (IMIDs), delivered by a focused immune intervention study examining brain circuitry using state of the art imaging in the context of exquisitely specific therapeutic immune interception in human immune disease. Glutamate concentration in the NAcc will be positively correlated with the magnitude of the inflammatory response and will be attenuated by IL-17A inhibition. Ultimately, this will be associated with an improvement in depressive symptoms. The strength of coupling between early and late systems will be attenuated in the context of IL-17A-driven inflammation and will be correlated with less frequent switching behaviour following negative outcomes and ultimately depressive symptoms. This coupling will be re-established following IL-17 antagonism. Patients whose depressive symptoms benefit most from IL-17A antagonism will exhibit greatest resting-state and task-specific functional connectivity between Th-NAcc.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06786936
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Secukinumab
Trials testing the same drug.
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07477795 — Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients · Phase 2 · not yet recruiting
- NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
- NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
- NCT06751238 — Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in · Phase 1 · recruiting
Other recruiting trials for Psoriatic Arthritis
Currently open trials in the same condition.
- NCT07286058 — Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis · Phase 3 · recruiting
- NCT07295509 — A Study of Picankibart in Patients With Active Psoriatic Arthritis · Phase 2, PHASE3 · recruiting
- NCT07290036 — A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adu · Phase 1 · recruiting
- NCT07180537 — Creating Health Course Study for People With Rheumatological Conditions · NA · recruiting
- NCT06888193 — A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® · Phase 1 · recruiting
Other NHS Greater Glasgow and Clyde trials
Trials by the same sponsor.
- NCT07403890 — Rewiring the Brain-Immune Axis for Chronic Pain Using Transcranial Magnetic Stimulation in Psoriatic Arthritis · NA · not yet recruiting
- NCT07372508 — Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions · NA · not yet recruiting
- NCT07391280 — Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department · NA · not yet recruiting
- NCT07048184 — Sarcoma Surgery Wound Complications Comparing Usual Versus Negative Pressure Dressing · Phase 2 · not yet recruiting
- NCT06821347 — NanO2 in Large VessEL Occlusion Stroke (NOVEL) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06786936 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NHS Greater Glasgow and Clyde
- Last refreshed: 19 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06786936.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing